Dynamic role of microparticles in type 2 diabetes mellitus.

Type 2 diabetes mellitus increases the risk of cerebro/cardiovascular events, since this disease leads to the development of premature atherosclerosis and atherothrombosis associated with diabetes accelerates diabetic macroangiopathy. Microparticles (MPs) released from cells (MPs) may play a role in the normal hemostatic response to vascular injury and a role in clinical diseases because they express phospholipids, which function as procoagulants. MPs were first observed as released vesicles from platelets following adhesion to vessel walls. Currently, the number of clinical disorders associated with elevated MPs is increasing. A few studies on the potential role of platelet-derived MPs in diabetic complications can been reported. MPs are elevated in diabetic patients however studies have found differences in the MP profile in relation to disease type and the presence or absence of MPs. Levels of platelet-derived MPs and monocyte-derived MPs have been shown to correlate with diabetic complications or the extent of diabetic retinopathy, which is associated with microvascular damage. Elevated endothelial cell-derived MP levels are predictive for the presence of coronary artery lesions, and it is a more significant independent risk factor than length of diabetic disease, lipid levels or presence of hypertension. Interestingly, elevated endothelial cell-derived MP levels are predictive in identifying a subpopulation of diabetic patients without typical anginal symptoms who have angiographic evidence of coronary artery disease. We will present evidence for a dynamic role of MPs in type 2 diabetes.

[1]  Wolfgang Schramm,et al.  Mechanism of platelet adhesion to von Willebrand factor and microparticle formation under high shear stress. , 2006, Blood.

[2]  P. Comfurius,et al.  Platelet procoagulant activity and microvesicle formation. Its putative role in hemostasis and thrombosis. , 1992, Biochimica et biophysica acta.

[3]  M. Nishikawa,et al.  Effect of Cilostazol on Soluble Adhesion Molecules and Platelet-derived Microparticles in Patients with Diabetes , 1998, Thrombosis and Haemostasis.

[4]  T. Iwasaka,et al.  Effect of valsartan on monocyte/endothelial cell activation markers and adiponectin in hypertensive patients with type 2 diabetes mellitus. , 2006, Thrombosis research.

[5]  J. Pugh,et al.  NIDDM is the Major Cause of Diabetic End-Stage Renal Disease: More Evidence From a Tri-Ethnic Community , 1995, Diabetes.

[6]  R. Holman,et al.  Relationship between ethnicity and glycemic control, lipid profiles, and blood pressure during the first 9 years of type 2 diabetes: U.K. Prospective Diabetes Study (UKPDS 55). , 2001, Diabetes care.

[7]  P. Grant.  Diabetes mellitus as a prothrombotic condition , 2007, Journal of internal medicine.

[8]  K. Ley,et al.  Proteomic discovery of 21 proteins expressed in human plasma-derived but not platelet-derived microparticles , 2006, Thrombosis and Haemostasis.

[9]  S. Nomura,et al.  Effects of efonidipine on platelet and monocyte activation markers in hypertensive patients with and without type 2 diabetes mellitus , 2002, Journal of Human Hypertension.

[10]  R. Nieuwland,et al.  Antigenic characterization of endothelial cell‐derived microparticles and their detection ex vivo , 2003, Journal of thrombosis and haemostasis : JTH.

[11]  S. Nomura,et al.  Enzyme immunoassay detection of platelet-derived microparticles and RANTES in acute coronary syndrome , 2003, Thrombosis and Haemostasis.

[12]  J. Freyssinet.  Cellular microparticles: what are they bad or good for? , 2003, Journal of thrombosis and haemostasis : JTH.

[13]  G. Mariani,et al.  Coagulation and fibrinolytic system impairment in insulin dependent diabetes mellitus. , 1992, Thrombosis research.

[14]  N. Takahashi,et al.  Probucol and ticlopidine: effect on platelet and monocyte activation markers in hyperlipidemic patients with and without type 2 diabetes. , 2004, Atherosclerosis.

[15]  S. Nomura,et al.  Cytometric analysis of high shear-induced platelet microparticles and effect of cytokines on microparticle generation. , 2000, Cytometry.

[16]  M. Matsumura,et al.  Increased levels of platelet-derived microparticles in patients with diabetic retinopathy. , 2005, Diabetes research and clinical practice.

[17]  S. Nomura,et al.  Platelet-derived microparticles may influence the development of atherosclerosis in diabetes mellitus. , 1995, Atherosclerosis.

[18]  S. Nomura,et al.  High-shear-stress-induced activation of platelets and microparticles enhances expression of cell adhesion molecules in THP-1 and endothelial cells. , 2001, Atherosclerosis.

[19]  G. FitzGerald,et al.  Arachidonic Acid in Platelet Microparticles Up-regulates Cyclooxygenase-2-dependent Prostaglandin Formation via a Protein Kinase C/Mitogen-activated Protein Kinase-dependent Pathway* , 1999, The Journal of Biological Chemistry.

[20]  A. Schroit,et al.  Loss of membrane phospholipid asymmetry in platelets and red cells may be associated with calcium-induced shedding of plasma membrane and inhibition of aminophospholipid translocase. , 1990, Biochimica et biophysica acta.

[21]  M. Lopes-Virella,et al.  Immune Mechanisms of Atherosclerosis in Diabetes Mellitus , 1992, Diabetes.

[22]  J. George,et al.  Platelet surface glycoproteins. Studies on resting and activated platelets and platelet membrane microparticles in normal subjects, and observations in patients during adult respiratory distress syndrome and cardiac surgery. , 1986, The Journal of clinical investigation.

[23]  L. Horstman,et al.  Endothelial cells release phenotypically and quantitatively distinct microparticles in activation and apoptosis. , 2003, Thrombosis research.

[24]  P. Sims,et al.  Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity. , 1988, The Journal of biological chemistry.

[25]  T. Iwasaka,et al.  Correlation between adiponectin and reduction of cell adhesion molecules after pitavastatin treatment in hyperlipidemic patients with type 2 diabetes mellitus. , 2008, Thrombosis research.

[26]  H. Deckmyn,et al.  Platelet microparticle formation and thrombin generation under high shear are effectively suppressed by a monoclonal antibody against GPIbα , 2006, Thrombosis and Haemostasis.

[27]  Mikhail A Panteleev,et al.  Platelet microparticle membranes have 50- to 100-fold higher specific procoagulant activity than activated platelets , 2007, Thrombosis and Haemostasis.

[28]  J. Freyssinet,et al.  Procoagulant Microparticles: Disrupting the Vascular Homeostasis Equation? , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[29]  J. Tait,et al.  Collagen-induced exposure of anionic phospholipid in platelets and platelet-derived microparticles. , 1991, The Journal of biological chemistry.

[30]  J. Freyssinet,et al.  Platelet microparticles and vascular cells interactions: A checkpoint between the haemostatic and thrombotic responses , 2008, Platelets.

[31]  T. Iwasaka,et al.  Long-term treatment with nifedipine modulates procoagulant marker and C-C chemokine in hypertensive patients with type 2 diabetes mellitus. , 2005, Thrombosis research.

[32]  A. Blann,et al.  Increased Levels of Soluble Adhesion Molecules in Type 2 (Non-Insulin Dependent) Diabetes mellitus Are Independent of Glycaemic Control , 1994, Thrombosis and Haemostasis.

[33]  J. Freyssinet,et al.  Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques: a role for apoptosis in plaque thrombogenicity. , 1999, Circulation.

[34]  Y. Ikeda,et al.  Function and role of microparticles in various clinical settings. , 2008, Thrombosis research.

[35]  G. FitzGerald,et al.  Transcellular activation of platelets and endothelial cells by bioactive lipids in platelet microparticles. , 1997, The Journal of clinical investigation.

[36]  G. Remuzzi,et al.  Progression, remission, regression of chronic renal diseases , 2001, The Lancet.

[37]  M. Nishikawa,et al.  Significance of chemokines and activated platelets in patients with diabetes , 2000, Clinical and experimental immunology.

[38]  Klaus Ley,et al.  The platelet microparticle proteome. , 2005, Journal of proteome research.

[39]  Patrice Darmon,et al.  Type 1 and type 2 diabetic patients display different patterns of cellular microparticles. , 2002, Diabetes.

[40]  A. Schafer.  The hypercoagulable states. , 1985, Annals of internal medicine.

[41]  L. Arnaud,et al.  Standardization of platelet‐derived microparticle counting using calibrated beads and a Cytomics FC500 routine flow cytometer: a first step towards multicenter studies? , 2009, Journal of thrombosis and haemostasis : JTH.

[42]  H. Ogura,et al.  Development and Assessment of Enzyme Immunoassay for Platelet-derived Microparticles , 2001, Thrombosis and Haemostasis.

[43]  P. Fontana,et al.  Cell-derived microparticles in haemostasis and vascular medicine , 2009, Thrombosis and Haemostasis.

[44]  T. Iwasaka,et al.  The effects of pitavastatin, eicosapentaenoic acid and combined therapy on platelet-derived microparticles and adiponectin in hyperlipidemic, diabetic patients , 2009, Platelets.

[45]  F. Gries,et al.  Large Platelets Circulate in an Activated State in Diabetes Mellitus , 1991, Seminars in thrombosis and hemostasis.

[46]  G. FitzGerald,et al.  Mechanisms of Cellular Activation by Platelet Microparticles , 1999, Thrombosis and Haemostasis.

[47]  M. Matsumura,et al.  Elevation of monocyte-derived microparticles in patients with diabetic retinopathy. , 2006, Diabetes research and clinical practice.

[48]  R. Nieuwland,et al.  Measuring circulating cell‐derived microparticles , 2004, Journal of thrombosis and haemostasis : JTH.

[49]  S. Haffner,et al.  Progression of Plasminogen Activator Inhibitor-1 and Fibrinogen Levels in Relation to Incident Type 2 Diabetes , 2006, Circulation.

[50]  F. Gries,et al.  Flow-cytometric detection of surface membrane alterations and concomitant changes in the cytoskeletal actin status of activated platelets. , 1990, Cytometry.

[51]  T. Iwasaka,et al.  Effect of nifedipine on adiponectin in hypertensive patients with type 2 diabetes mellitus , 2007, Journal of Human Hypertension.

[52]  U. Garbin,et al.  E-Selectin plasma concentration is influenced by glycaemic control in NIDDM patients: possible role of oxidative stress , 1997, Diabetologia.

[53]  Mona D. Shah,et al.  Flow cytometric measurement of microparticles: Pitfalls and protocol modifications , 2008, Platelets.

[54]  Y Komiyama,et al.  High shear stress can initiate both platelet aggregation and shedding of procoagulant containing microparticles. , 1996, Blood.

[55]  A. Nurden,et al.  Procoagulant activity and active calpain in platelet-derived microparticles. , 1996, Thrombosis research.

[56]  R. Nieuwland,et al.  Elevated Numbers of Tissue-Factor Exposing Microparticles Correlate With Components of the Metabolic Syndrome in Uncomplicated Type 2 Diabetes Mellitus , 2002, Circulation.

[57]  G. London,et al.  In Vivo Shear Stress Determines Circulating Levels of Endothelial Microparticles in End-Stage Renal Disease , 2007, Hypertension.

[58]  S. Nomura,et al.  Effects of eicosapentaenoic acid on platelet activation markers and cell adhesion molecules in hyperlipidemic patients with Type 2 diabetes mellitus. , 2003, Journal of diabetes and its complications.

[59]  Y. Komiyama,et al.  Amyloid β-Protein Precursor-Rich Platelet Microparticles in Thrombotic Disease , 1994, Thrombosis and Haemostasis.

[60]  P Lesavre,et al.  Increase of circulating neutrophil and platelet microparticles during acute vasculitis and hemodialysis. , 2006, Kidney international.

[61]  A. Wolberg,et al.  Tissue factor de-encryption: ionophore treatment induces changes in tissue factor activity by phosphatidylserine-dependent and -independent mechanisms. , 1999, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[62]  L. Niskanen,et al.  Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in Type 2 (non-insulin-dependent) diabetic and non-diabetic subjects , 1993, Diabetologia.

[63]  Toshiji Iwasaka,et al.  Effects of Losartan and Simvastatin on Monocyte-Derived Microparticles in Hypertensive Patients With and Without Type 2 Diabetes Mellitus , 2004, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[64]  Christian Weber,et al.  Platelet Microparticles: A Transcellular Delivery System for RANTES Promoting Monocyte Recruitment on Endothelium , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[65]  A. Fitzgerald,et al.  Microalbuminuria and coronary heart disease in NIDDM: an incidence study. , 1998, Diabetes.

[66]  F. Dignat-George,et al.  Interaction of endothelial microparticles with monocytic cells in vitro induces tissue factor-dependent procoagulant activity. , 2002, Blood.

[67]  C. Erem,et al.  Coagulation and Fibrinolysis Parameters in Type 2 Diabetic Patients with and without Diabetic Vascular Complications , 2004, Medical Principles and Practice.

[68]  L. Horstman,et al.  Endothelial microparticles and platelet and leukocyte activation in patients with the metabolic syndrome. , 2006, The American journal of cardiology.

[69]  T. Nakayama,et al.  Level, distribution and correlates of platelet-derived microparticles in healthy individuals with special reference to the metabolic syndrome , 2008, Thrombosis and Haemostasis.

[70]  B. Furie,et al.  Platelet-derived microparticles express high affinity receptors for factor VIII. , 1991, The Journal of biological chemistry.

[71]  T. Iwasaka,et al.  Activated Platelet and Oxidized LDL Induce Endothelial Membrane Vesiculation: Clinical Significance of Endothelial Cell-Derived Microparticles in Patients With Type 2 Diabetes , 2004, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[72]  Y. Castier,et al.  Cellular origins and thrombogenic activity of microparticles isolated from human atherosclerotic plaques. , 2007, Journal of the American College of Cardiology.

[73]  S. Nomura,et al.  Differences between platelet and microparticle glycoprotein IIb/IIIa. , 1992, Cytometry.

[74]  L. Horstman,et al.  Platelet microparticles bind, activate and aggregate neutrophils in vitro. , 1995, Blood cells, molecules & diseases.

[75]  M. Monden,et al.  Platelet microparticles: a carrier of platelet-activating factor? , 1996, Biochemical and biophysical research communications.

[76]  D. Monroe,et al.  Coagulation Factor IXa Binding to Activated Platelets and Platelet-Derived Microparticles: A Flow Cytometric Study , 1992, Thrombosis and Haemostasis.

[77]  S. Novo,et al.  Increased levels of C-reactive protein and fibrinogen influence the risk of vascular events in patients with NIDDM. , 2006, International journal of cardiology.

[78]  R. Colman,et al.  Truncated and microparticle-free soluble tissue factor bound to peripheral monocytes preferentially activate factor VII , 2005, Thrombosis and Haemostasis.

[79]  R. Nieuwland,et al.  Microparticles in cardiovascular diseases. , 2003, Cardiovascular research.

[80]  G. FitzGerald,et al.  Modulation of monocyte-endothelial cell interactions by platelet microparticles. , 1998, The Journal of clinical investigation.